未登录 Safety, pharmakokinetics and antiviral activity of novel capsid assembly modulator (CAM) JNJ-56136379 (JNJ-6379) in treatmentnaive chronic hepatitis B (CHB) patients without cirrhosis Zoulim, F.; Yogaratnam, J. Z.; Vandenbossche, J. J.; Lenz, O.; Talloen, W.; Vistuer, C.; Moscalu, I.; Streinu-Cercel, A.; Bourgeois, S.; Buti, M.; Crespo, J.; Pascasio, J. M.; Sarrazin, C.; Vanwolleghem, T.; Blatt, L.; Fry, J. 分享 收藏
分享 收藏
分享 收藏
The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without pegylated interferon: a Belgian experience Bielen, R.; Moreno, C.; Van Vlierberghe, H.; Bourgeois, S.; Mulkay, J. -P.; Francque, S.; Verlinden, W.; Brixko, C.; Decaestecker, J.; De Galocsy, C.; Janssens, F.; Cool, M.; Van Steenkiste, C.; D'heygere, F.; Wuyckens, K.; Nevens, F.; Robaeys, G. 分享 收藏
Review of transnational nursing education programme curricula: process, findings, and recommendations Mackay, Maria; Joyce-McCoach, Joanne; Stephens, Moira; Cutler, Natalie; Brown, Roy; Fernandez, Ritin; Froggatt, Terry J.; Heaton, Leeanne; Moxham, Lorna; Sim, Jenny; Traynor, Victoria; Bourgeois, Sharon 分享 收藏
PHARMACOKINETIC INTERACTIONS BETWEEN SIMEPREVIR AND LEDIPASVIR IN TREATMENT-NAIVE HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS WITHOUT CIRRHOSIS TREATED WITH A SIMEPREVIR/SOFOSBUVIR/LEDIPASVIR REGIMEN Bourgeois, S.; Horsmans, Y.; Nevens, F.; van Vlierberghe, H.; Moreno, C.; Beumont, M.; van de Logt, J.; Vijgen, L.; van Eygen, V.; Luo, D.; Hillewaert, V.; Van Remoortere, P.; Ouwerkerk-Mahadevan, S. 分享 收藏
EFFICACY AND TOLERABILITY OF SIMEPREVIR AND DACLATASVIR FOR 12 OR 24 WEEKS IN HCV GENOTYPE 1B-INFECTED TREATMENT-NAIVE PATIENTS WITH ADVANCED FIBROSIS OR COMPENSATED CIRRHOSIS Hezode, C.; Almasio, P.; Bourgeois, S.; Buggisch, P.; Brown, A.; Diago, M.; Horsmans, Y.; Serfaty, L.; Szalay, F.; Gaeta, G. B.; Planas, R.; Schlag, M.; Lonjon-Domanec, I.; Gilles, L.; DeMasi, R.; Zeuzem, S. 分享 收藏
THE TOLERABILITY OF SOF/VEL FOR 12 WEEKS IN >1,000 PATIENTS TREATED IN THE ASTRAL-1, ASTRAL-2, AND ASTRAL-3 STUDIES: AN INTEGRATED SAFETY ANALYSIS Jacobson, I.; Brau, N.; Bourgeois, S.; Mathurin, P.; Thuluvath, P.; Fessel, W. J.; Ryder, S.; Gerken, G.; Liu, L.; Ding, X.; McNally, J.; Osinusi, A.; Brainard, D.; Subramanian, M.; Foster, G. 分享 收藏
ON TREATMENT HCV RNA AS A PREDICTOR OF SVR12 IN PATIENTS WITH GENOTYPE 1-6 HCV INFECTION TREATED WITH SOFOSBUVIR/VELPATASVIR FIXED DOSE COMBINATION FOR 12 WEEKS: AN ANALYSIS OF THE ASTRAL-1, ASTRAL-2, AND ASTRAL-3 STUDIES Alqatani, S.; Zeuzem, S.; Bourgeois, S.; Mathurin, P.; Rojter, S.; Everson, G.; Abergel, A.; De Ledinghen, V.; Liu, L.; Ding, X.; Mcnally, J.; Osinusi, A.; Brainard, D.; Subramanian, M.; Mangia, A.; Sulkowski, M. 分享 收藏
ONCE-DAILY SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE OR TREATMENT-EXPERIENCED CHRONIC HCV GENOTYPE 4-INFECTED PATIENTS: FINAL RESULTS OF A PHASE III TRIAL Moreno, C.; Hezode, C.; Marcellin, P.; Bourgeois, S.; Francque, S.; Samuel, D.; Zoulim, F.; Grange, J. -D.; Lenz, O.; Ouwerkerk-Mahadevan, S.; Peeters, M.; Beumont-Mauviel, M.; Jessner, W. 分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
.png){kind=icon}
未登录.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
